Citigroup Inc. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 17.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,680 shares of the biotechnology company’s stock after purchasing an additional 33,471 shares during the quarter. Citigroup Inc. owned approximately […]
Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently bolstered its investment in Exelixis Inc (NASDAQ:EXEL), a notable player in the biopharmaceutical industry. The transaction, which took place on December 19, 2023, saw the firm adding 398,800 shares to its holdings, reflecting a 2.62% change in the position size.
Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Investment analysts at William Blair increased their Q2 2024 EPS estimates for shares of Exelixis in a research note issued on Wednesday, February 7th. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings of $0.27 per share for the quarter, up from their […]